
Formulary Search
You are here : Home > Formulary Search
Search Results : Alzheimers disease (Donanemab - Alzheimers disease)
Show Icon and Status Keys Hide Icon and Status Keys
Icon Key



Status Key
- Intravenous infusion
This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here (for a similar drug called lecanemab) which provides advice on potential adverse effects.
- Not Specified
- Intravenous infusion
Lecanemab used in Alzheimer’s disease is currently not available in the NHS. Eisai (the manufacturer and market authorisation holder for lecanemab (Leqembi®)) has started to make the drug available for patients to access through independent sector clinics.
The information from NHSE here provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).